Drugs targeting functional bowel disorders: Lessions from drug trials

Current Opinion in Pharmacology

Volumn 2, Issue 6, 2002, Pages 684-690

  Camilleri, Michael ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 ACETOXYMETHYL 3 [7 [[1 (N,N DIMETHYLCARBAMOYL) 6 (4 FLUOROPHENYL) 3 INDOLYL]CARBONYL] 1H,3H PYRROLO[1,2 C]THIAZOL 3 YL]PYRIDINIUM CHLORIDE; ALOSETRON; CILANSETRON; CISAPRIDE; ERYTHROMYCIN; MOTILIN; PROKINETIC AGENT; SEROTONIN 4 AGONIST; SEROTONIN TRANSPORTER; TEGASEROD; GASTROINTESTINAL AGENT;

CLINICAL STUDY; CONSTIPATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; DYSPEPSIA; ENTEROPATHY; EPIGASTRIC PAIN; HEARTBURN; HUMAN; IRRITABLE COLON; NAUSEA; PHARMACODYNAMICS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; STOMACH DISEASE; STOMACH DISTENSION; STOMACH EMPTYING; CLINICAL TRIAL; GASTROINTESTINAL DISEASE; METHODOLOGY; PATIENT SELECTION; REPRODUCIBILITY; RISK ASSESSMENT; STANDARD;

CLINICAL TRIALS; GASTROINTESTINAL AGENTS; GASTROINTESTINAL DISEASES; HUMANS; PATIENT SELECTION; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

EID: 0036902492     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-4892(02)00224-2     Document Type: Review

References (42)

1. Camilleri M: Management of the irritable bowel syndrome. Gastroenterology 2001, 120:652-668.
2. Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR: Design of treatment trials for the functional gastrointestinal disorders. In Rome II: The Functional Gastrointestinal Disorders, edn 2. Edited by Drossman DA. McLean, Virginia: Degnon Associates; 2000:577-622.
3. Moher D, Schulz KF, Altman D, the CONSORT Group: The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. J Am Med Assoc 2001, 285:1987-1990.
4. Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA: Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995, 109:40-52.
5. Lembo T, Munakata J, Mertz H, Niazi N, Kodner A, Nikas V, Mayer EA: Evidence for the hypersensitivity of lumbar splanchnic afferents in irritable bowel syndrome. Gastroenterology 1994, 107:1686-1696.
6. Lembo T, Naliboff B, Munakata J, Fullerton S, Saba L, Tung S, Schmulson M, Mayer EA: Symptoms and visceral perception in patients with pain-predominant irritable bowel syndrome. Am J Gastroenterol 1999, 94:1320-1326.
7. Lembo T, Naliboff BD, Matin K, Munakata J, Parker RA, Gracely RH, Mayer EA: Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 2000, 87:137-147.
8. Riberdy-Poitras M, Verrier P, Plourde V, Boivin M, Poitras P: Amitryptilin for the treatment of IBS [abstract]. Gastroenterology 2000, 118:A617.
9. 3 antagonist in subjects with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001, 92:2671-2676.
10. Caras S, Krause G, Biesheuvel E, Steinborn C: Cilansetron shows efficacy in male and female non-constipated patients with irritable bowel syndrome in a United States study [abstract]. Gastroenterology 2001, 120:A217.
11. 4 receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001, 15:1655-1666.
12. 3-receptor antagonist. Aliment Pharmacol Ther 1999, 13:1149-1159.
13. Camilleri M, Northcutt AR, Kong S, Dukes GE, McSorley D, Mangel AW: Efficacy and safety of alosetron in women with irritable bowel syndrome: a randomised, placebo-controlled trial. Lancet 2000, 355:1035-1040.
14. Camilleri M, Chey WY, Mayer EA, Northcutt AR, Heath A, Dukes GE, McSorley D, Mangel AW: A randomized controlled clinical trial of the serotonin type 3 receptor antagonist, alosetron, in women with diarrhea-predominant irritable bowel syndrome. Arch Intern Med 2001, 161:1733-1740.
15. Jones RH, Holtmann G, Rodrigo L, Ehsanullah RS, Crompton PM, Jacques LA, Mills JG: Alosetron relieves pain and improves bowel function compared with mebeverine in female nonconstipated irritable bowel syndrome patients. Aliment Pharmacol Ther 1999, 13:1419-1427.
16. Tegaserod data summarized from presentation to Advisory Committee of Food and Drug Administration. 2000, URL: http://www.fda.gov/ohrms/dockets/ac/00/backgrd/3627b1a.pdf
17. Redelmeier DA, Guyatt GH, Goldstein RS: Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol 1996, 49:1215-1219.
18. Guyatt GH, Juniper EF, Walter SD, Griffith LE, Goldstein RS: Interpreting treatment effects in randomised trials. BMJ 1998, 316:690-693.
19. Watson ME, Lacey L, Kong S, Northcutt AR, McSorley D, Hahn B, Mangel AW: Alosetron improves quality of life in women with diarrhea-predominant irritable bowel syndrome. Am J Gastroenterol 2001, 96:455-459.
20. Hahn B, Watson M, Yan S, Gunput D, Heuijerjans J: Irritable bowel syndrome symptom patterns: frequency, duration, and severity. Dig Dis Sci 1998, 43:2715-2718.
21. Evans WE, Relling MV: Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286:487-491.
22. Genain CP, Zamvil SS: Specific immunotherapy: one size does not fit all. Nat Med 2000, 6:1098-1100.
23. McLeod HL, Evanc WE: Pharmacogenomics: unlocking the human genome for better drug therapy. Annu Rev Pharmacol Toxicol 2001, 41:101-121.
24. Camilleri M, Atanasova E, Carlson PJ, Ahmad U, Kim HJ, Viramontes BE, McKinzie S, Urrutia R: Serotonin transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome. Gastroenterology 2002, 123:425-432.
25. Camilleri M: Comment from the editors: ten secrets for development of drugs for functional gastrointestinal diseases. Gastroenterology 2000, 118:653.
26. Camilleri M: Letter to the editor: motilin agonists and dyspepsia: throwing out the baby with the bath water. Gut 2002, 51:612.
27. Talley NJ, Verlinden M, Snape W, Beker JA, Ducrotte P, Dettmer A, Brinkhoff H, Eaker E, Ohning G, Miner PB et al.: Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000, 14:1653-1661.
28. Talley NJ, Verlinden M, Geenen DJ, Hogan RB, Riff D, McCallum RW, Mack RJ: Effects of a motilin receptor agonist (ABT-229) on upper gastrointestinal symptoms in type 1 diabetes mellitus: a randomised, double blind, placebo controlled trial. Gut 2001, 49:395-401.
29. Tack J, Peeters T: What comes after macrolides and other motilin stimulants? Gut 2001, 49:317-318.
30. Maes BD, Mys G, Geypens BJ, Evenepoel P, Ghoos YF, Rutgeerts PJ: Gastric emptying flow curves separated from carbon-labeled octanoic acid breath test results. Am J Physiol 1998, 275:G169-175.
31. 13C]octanoic acid breath test. Am J Gastroenterol 2000, 95:2751-2761.
32. Lee J-S, Camilleri M, Zinsmeister AR, Burton DD, Kost LJ, Klein PD: A valid, accurate, office-based, nonradioactive test for gastric emptying of solids. Gut 2000, 46:768-773.
33. Viramontes BE, Kim D-Y, Camilleri M, Lee JS, Daniel D, Burton DD, Thomforde GM, Klein PD, Zinsmeister AR: Validation of a stable isotope gastric emptying test for normal, accelerated or delayed gastric emptying. Neurogastroenterol Mot 2001, 13:567-574.
34. Verhagen MA, Samsom M, Maes B, Geypens BJ, Ghoos YF, Smout AJ: Effects of a new motilide, ABT-229, on gastric emptying and postprandial antroduodenal motility in healthy volunteers. Aliment Pharmacol Ther 1997, 11:1077-1086.
35. Jian R, Ducrot F, Ruskone A, Chaussade S, Rambaud JC, Modigliani R, Rain JD, Bernier JJ: Symptomatic, radionuclide and therapeutic assessment of chronic idiopathic dyspepsia. A double-blind placebo-controlled evaluation of cisapride. Dig Dis Sci 1989, 34:657-664.
36. Janssens J, Peeters TL, Vantrappen G, Tack J, Urbain JL, De Roo M, Muls E, Bouillon R: Improvement of gastric emptying in diabetic gastroparesis by erythromycin. Preliminary studies. N Engl J Med 1990, 322:1028-1031.
37. Tack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J: Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998, 115:1346-1352.
38. Kim D-Y, Delgado-Aros S, Camilleri M, Samsom M, Murray JA, O'Connor MK, Brinkmann BH, Stephens DA, Lighvani SS, Burton DD: Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol 2001, 96:3099-3105.
39. Bruley des Varannes S, Parys V, Ropert A, Chayvialle JA, Roze C, Galmiche JP: Erythromycin enhances fasting and postprandial proximal gastric tone in humans. Gastroenterology 1995, 109:32-39.
40. Liau S-S, Camilleri M, Kim D-Y, Stephens D, Burton DD, O'Connor MK: Pharmacological modulation of human gastric volumes demonstrated noninvasively using SPECT imaging. Neurogastroenterol Motil 2001, 13:533-542.
41. Rayner CK, Samsom M, Jones KL, Horowitz M: Relationships of upper gastrointestinal motor and sensory function with glycemic control. Diabetes Care 2001, 24:371-381.
42. Samsom M, Salet GA, Roelofs JM, Akkermans LM, Vanberge-Henegouwen GP, Smout AJ: Compliance of the proximal stomach and dyspeptic symptoms in patients with type I diabetes mellitus. Dig Dis Sci 1995, 40:2037-2042.